
Your Reliable Partner for Cell & Gene Therapy GMP Manufacturing



SCTbio is a European global contract development and manufacturing organization for Advanced Therapy Medicinal Products (ATMPs). Founded as a spin-off from SOTIO, member of PPF Group, to directly address the growing demand for cell and gene therapy manufacturing, SCTbio holds over a decade of experience developing best-in-class clinical manufacturing services, development solutions and technologies transfer.





Cutting-Edge GMP Manufacturing Facility and Capabilities

The company operates a cutting edge GMP manufacturing facility with 420 m² (4,520 ft²) grade A/B/C/D clean rooms classified according to EU cGMP



- Fully segregated clean room facility
- Separated microbiology clean premises 60 m²
- Class B manufacturing suites of 26 m²
 and 13 m² (ca. 200 m² in total)
- GMO with viral/nonviral origin in different sections without risk of cross-contamination
 - Aseptic fill and finish capabilities
 - Cell culturing and cell banking
 - Ability to manufacture different products including GMO with viral/non-viral origin in different sections without risk of cross-contamination
 - Class C premises with large cryostorage capacities

Scope of Services

SCTbio has strong expertise in all needle-to-needle GMP operations, including validated apheresis collection sites network, product manufacturing, QC, GMP storage, QA/QP release and worldwide drug products supply



SCTbio offers end-to-end manufacturing and development services to accelerate your cell and gene therapy programs

150 Apheresis Centers

3,000 collections

24-48h*
lead time

12,000 IMP's delivered

10+
clinical
studies

* EUROPE: up to 24hrs (destination-dependent); USA: 30-48hrs (transport-dependent)

